Filter Specialty
Submit To The Journals

88/Cardiac sarcoid and implantable cardioverter defibrillators – Should guidelines be expanded?

European Journal of Arrhythmia & Electrophysiology. 2019;5(Suppl. 1):abstr88

Introduction: Symptomatic cardiac involvement occurs in ~5% of patients with sarcoidosis, with up to ~25% occurrence seen in autopsy studies. Ventricular arrhythmias and cardiac arrest may be the first presenting event in otherwise asymptomatic patients. Implantable cardioverter-defibrillators (ICDs) are frequently deployed, but only a weak evidence base exists.

Methods: We retrospectively reviewed the indication for ICD implantation in patients known to the Cardiac Sarcoid Service at Barts Heart Centre, the frequency of upgrade from permanent pacemaker (PPM) and examined the rates of appropriate and inappropriate shocks.

Results: Records from 101 patients with suspected or confirmed cardiac sarcoid (CS) seen at Barts Heart Centre between 2015 and 2019 were reviewed. 11 patients had PPMs implanted. Twenty-seven patients had ICDs implanted. Six of these were female, 21 were male and mean age was 52 ± 12 years. Sixteen patients had CRT-Ds in situ, 4 of which had been upgraded from a previous ICD and 5 of which had been upgraded from a previous PPM. Eleven patients had ICDs in situ, one of which had been upgraded from a previous PPM. Fifteen patients had primary prevention ICDs and 12 patients had secondary prevention ICDs.

A total of 154 patient years with ICDs in situ were recorded for these 27 patients. Six patients have received appropriate shocks, five of these patients had secondary prevention ICDs. No patients received inappropriate shocks. Three of those with ICDs who received shocks had a left ventricular ejection fraction (LVEF) of <35%, while 3 had a LVEF >50%. Of appropriate shocks delivered, 50% of those were for ventricular tachycardia and 50% were for ventricular fibrillation. In the single patient who had a shock from a primary prevention ICD, the device was implanted for a pacing indication and deteriorating LV function, with an ejection fraction of <25% at the time of shock which occurred 5 years after implantation.


Conclusion: In this group of cardiac sarcoid patients with ICDs in situ, no shocks were delivered in patients with primary prevention devices and mild/moderately impaired or good LV function. We will continue to collect this data from our Cardiac Sarcoid Service to provide greater clarity as to the use of ICDs in this population.

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchcardio is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.